Health Economics›Non-small cell lung cancer›Advanced or metastatic disease ALK inhibitor-naive

Advanced or metastatic disease ALK inhibitor-naive

Non-small cell lung cancer · 10 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 8 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Crizotinib monotherapy Variant #01	ALK	R 119 525	28d	11.1 mo	—	13	R 1 553 824 PFS proxy	12
Brigatinib monotherapy Variant #01	ALK	R 50 797	28d	21.7 mo	—	24	R 1 219 118 PFS proxy	2
Ceritinib monotherapy Variant #01	ALK	R 35 198	28d	11.0 mo	—	12	R 422 372 PFS proxy	2
Cisplatin and Pemetrexed Variant #01	ALK	R 1 088	21d	5.5 mo	22.5 mo	8	R 8 701 PFS proxy	20
Docetaxel monotherapy N/A - secondary systemic drug	ALK	R 243	28d	1.6 mo	—	2	R 486 PFS proxy	4
Alectinib monotherapy Variant #01	ALK	R 108	28d	27.0 mo	—	30	R 3 229 PFS proxy	7
Pemetrexed monotherapy N/A - secondary systemic drug	ALK	R 69	21d	1.6 mo	—	3	R 208 PFS proxy	3
Carboplatin and Pemetrexed N/A - secondary systemic drug	ALK	R 52	21d	5.6 mo	22.5 mo	9	R 469 PFS proxy	18
Lorlatinib monotherapy Variant #01 Partial	ALK	—	28d	—	—	—	—	2
Ensartinib monotherapy Variant #01 Partial	ALK	—	28d	25.8 mo	—	29	—	1

10 of 10 regimens shown